Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Entrada Therapeutics (TRDA) Assets Average (2022 - 2025)

Historic Assets Average for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to $430.8 million.

  • Entrada Therapeutics' Assets Average fell 2418.47% to $430.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $430.8 million, marking a year-over-year decrease of 2418.47%. This contributed to the annual value of $497.8 million for FY2024, which is 3802.64% up from last year.
  • As of Q3 2025, Entrada Therapeutics' Assets Average stood at $430.8 million, which was down 2418.47% from $467.6 million recorded in Q2 2025.
  • Entrada Therapeutics' Assets Average's 5-year high stood at $568.3 million during Q3 2024, with a 5-year trough of $263.3 million in Q4 2022.
  • For the 4-year period, Entrada Therapeutics' Assets Average averaged around $444.3 million, with its median value being $480.9 million (2023).
  • Its Assets Average has fluctuated over the past 5 years, first soared by 8123.28% in 2023, then tumbled by 2418.47% in 2025.
  • Over the past 4 years, Entrada Therapeutics' Assets Average (Quarter) stood at $263.3 million in 2022, then skyrocketed by 81.23% to $477.1 million in 2023, then grew by 13.28% to $540.5 million in 2024, then decreased by 20.28% to $430.8 million in 2025.
  • Its Assets Average was $430.8 million in Q3 2025, compared to $467.6 million in Q2 2025 and $506.4 million in Q1 2025.